As such, programmed cell death protein 1 (PD-1) checkpoint blockade—inhibition of T cell apoptosis by preventing binding to PD-1, known to modify AD [87]—in conjunction with the influenza vaccine, is hypothesised to have a dual immunostimulatory effect that could provide clinical benefit. The gene discussed is PDCD1; the disease is Alzheimer disease.